Rockville, MD, April 2, 2017 –  Precision-Biologics Inc. today announced an abstract reporting data on the company’s neo-antigen program has been accepted for an oral presentation at the upcoming 110th Annual Meeting of the American Association of Clinical Research (AACR) in Washington D.C., April 1-5, 2017.

“Precision Biologics continues to make progress with our preclinical and clinical programs,” said Philip M. Arlen, President and CEO of Precision Biologics. “As this study demonstrates, our novel, humanized IgG1 monoclonal antibody, NEO-201, specifically targets a neoantigen expressed on a broad range of solid tumors. Tumor cell killing, antibody-dependent, cell-mediated cytotoxicity (ADCC), was significantly enhanced when NEO-201 was combined with an allogenic source of natural killer cells provided by NantKwest (Nasdaq:NK).”

Patrick Soon-Shiong, MD, Chairman and CEO of NantCell added, “These results highlight the potential to synergistically improve the response of antibody therapy when used in combination with NantKwest’s off-the-shelf natural killer cells.” Dr. Soon-Shiong continued,” Neoantigen targeting is an attractive, emerging therapeutic approach to next generation cancer care and NEO-201, with specificity to tumor tissues and not normal tissues, offers the potential to further improve response rates and look to transitioning this NEO-201/NK cell combination into human clinical trials targeting ovarian, GI and other cancer types as quickly as possible.”

Presentation Summary

Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies

This oral presentation will present preclinical data demonstrating the potential benefit of targeting the NEO-201 neoantigen in both cancer cell lines as well as patient’s tumors.   NEO-201 monoclonal antibody was shown to mediate ADCC activity, which was further enhanced when used with allogenic natural killer cells in tumor cell lines expressing the NEO-201 neoantigen. The NEO-201 antigen is expressed on numerous solid tumors with minimal expression on healthy tissue. The company plans to move this program into human clinical trials in the near future.

In October 2015, NantCell Inc., a subsidiary of NantWorks, LLC, acquired a majority stake in Precision Biologics with a $50 million investment. NantCell made the investment to further its efforts to activate the human immune system to treat the biology of cancer and avoid the toxic effects of standard chemotherapy. With Precision Biologics proprietary library of cancer vaccines, NantCell is working on developing compounds that could change the way cancer is detected and treated.

About Precision Biologics

Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company’s antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today’s breakthrough technologies, the company is developing antibody therapeutics that could change the way we detect and treat cancer. For more information on Precision Biologics, please visit

About NantCell

NantCell, a wholly-owned subsidiary of NantWorks, LLC, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by developing molecularly targeted therapeutics, based on the proteomic profile of the patient’s tumor, independent of the cancer’s anatomical type.

NantCell’s mission is to make obsolete the standard method of clinical trial design of “trial and error” and replace it with a level of quantitative predictability based on both the genomic and proteomic profile performed a priori. The Company will tap into comprehensive “omic” analytic tools and “big data” generated from supercomputing to develop molecularly designed drugs in this era of genomics and proteomics and identify patients and their tumor signature at the most granular cellular, DNA and protein levels. Patients entering clinical trials would be identified after a comprehensive “omic” analysis from tissue to cell to DNA to RNA to protein to peptide to drug, and tested based on this molecular profile to maximize clinical outcome and minimize side effects. Through these integrated diagnostic methods, the company is pursuing the vision of treating the biology of cancer rather than the anatomy, and drive the immune system inherited by all to defeat cancer.  For more information please visit and follow Dr. Soon-Shiong on Twitter @Dr.PatSoonShiong.


Media Contact:

Jen Hodson